Shares of Citius Pharmaceuticals (CTXR) tumbled 11.3% to $0.67 after the company's fiscal third-quarter report on August 14 revealed a painful mismatch: its cancer therapy is winning over hospitals, but not fast enough to keep the lights on without fresh capital.

  • Revenue Slowed When It Needed to Accelerate. For the three months ended June 30, 2026, Citius recorded $1.5 million in revenue and gross profit of $1.0 million, a roughly 67% gross margin. That's a sharp sequential decline from the $3.9 million first quarter and $1.67 million second quarter. Nine-month revenue reached $7.1 million with a roughly 77% gross margin — respectable for a drug launched only in December 2025, but the quarterly trajectory shows sales flattening right when investors expected a ramp. The miss signals that converting hospital formulary access into actual prescriptions is proving slow.

  • Three Months of Cash Left Is a Survival Problem. Cash and cash equivalents were $17.0 million at June 30, 2026.

Management explicitly highlights "substantial doubt about continuing as a going concern" beyond November 2026 without new capital.

The Q3 net loss was $8.9 million, with nine-month losses totaling $38.3 million. At that burn rate, November is arithmetic, not speculation. Any new financing — whether stock sales or debt — will likely dilute current shareholders or add costly interest obligations.

  • Hospital Orders Are Rising, but From a Tiny Base. Institutional vial orders grew 31% sequentially, from 708 to 926 vials quarter over quarter.

In July alone, institutions ordered 383 vials, the largest single month to date.

The drug is now available at 44 institutions, and new ordering institutions increased 80%. The growth is real, but 926 vials in a quarter is a tiny number for a market management estimates at over $400 million.

  • The Sales Machine Is Expensive and Just Getting Started. Citius Oncology completed the nationwide deployment of 29 commercial and medical affairs professionals. That team is now fully on payroll, which explains why losses nearly doubled year-over-year. The company targets 100 priority institutions for formulary inclusion by year-end — a goal that will require sustained spending.

The core tension is clear: the drug is working clinically, but the company is burning cash far faster than revenue is arriving. Shareholders face near-certain dilution before Thanksgiving.